About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Route 92 Medical Files Patent Infringement Suit Against Balt

By: via GlobeNewswire

SAN MATEO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, filed a patent infringement lawsuit against Balt USA, LLC (Balt) alleging infringement of five U.S. patents held by Route 92 Medical that protect the Tenzing® delivery technology. The complaint was filed on August 6, 2025, in the U.S. District Court for the District of Delaware.

“We believe Route 92 Medical has a differentiated portfolio of complete solutions for neurovascular interventional procedures each supported by our proprietary and patented Tenzing delivery technology,” said Tony Chou, M.D., Founder and Chief Executive Officer of Route 92 Medical. “Results using our products published in peer-reviewed journals demonstrate high rates of ability to reach and remove a clot on the first pass. These publications include both our FreeClimb® reperfusion systems and HiPoint® reperfusion systems featuring the Monopoint® approach, all featuring Tenzing delivery technology. We believe the market success of these products is a testament to the clinical outcomes that are achieved with their use. We will continue to vigorously defend the patents that protect our innovations worldwide.”

Tenzing delivery technology is currently protected by a global portfolio of patents, including over 30 U.S. patents. Tenzing catheters offer a soft and tapered tip designed to minimize ledge effect and to provide atraumatic tracking in the neurovasculature without the use of a microcatheter. The Tenzing delivery catheters are available in three sizes, each designed to be delivered together with Route 92 Medical’s HiPoint or FreeClimb catheters as part of a seamless system to enhance the efficacy of neurovascular procedures. These devices have been evaluated in physician-initiated, peer-reviewed studies across multiple vessel sizes and device lengths.

Route 92 Medical’s continued innovation depends upon its ability to protect its products globally. The company continues to expand its patent portfolio as it innovates and has recently secured additional patents covering products in its Monopoint family, including its Tenzing delivery technology.

As part of its ongoing innovation program, Route 92 Medical recently announced results from its SUMMIT MAX clinical trial (NCT05018650), which represents the highest level of clinical evidence as the only prospective, randomized, controlled, endovascular stroke thrombectomy trial of a super-bore catheter. The 250-patient, multicenter, trial evaluated the safety and efficacy of the HiPoint reperfusion system, which included a “super-bore” aspiration catheter with an 0.088-inch inner diameter, for the treatment of a large vessel occlusion, the cause of many acute ischemic strokes. The clinical trial showed delivery of the HiPoint 88 aspiration catheter to the M1 segment of the middle cerebral artery (MCA) using the Tenzing delivery technology was achieved 90.1% of the time compared to the smaller 0.074-inch control catheter, which reached the M1 segment 71.6% of the time. In the trial, the Route 92 Medical arm achieved the highest first pass effect rates reported in a randomized controlled trial with a consistent safety profile.

In May 2025, the company announced receipt of U.S. Food and Drug Administration 510(k) clearance for its HiPoint 88 reperfusion system, which allows direct aspiration of the thrombus with the HiPoint 88 aspiration catheter.

About Route 92 Medical, Inc.

Route 92 Medical is on a mission to improve outcomes for acute ischemic stroke patients undergoing neurovascular intervention and reduce suffering for these patients and their families by consistently reaching the clot, increasing first pass effect rates and simplifying the procedure with our systems. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn.


Contacts: For Media

Gwen Gordon
858-245-5684
Gwen@gwengordonpr.com

Primary Logo

More News

View More
Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally
Via MarketBeat
Tickers AMZN
Let the Good Times Roll: 2 Stocks Showing No Signs of Slowing
Via MarketBeat
Topics Artificial Intelligence World Trade
Tickers ATRO INOD META
Café Culture Revival? 3 Stocks to Watch After Chick-fil-A’s Move
Via MarketBeat
Tickers CMG MCD SBUX YUM
Carmakers Step in With Incentives as EV Tax Credit Expires
Via MarketBeat
Topics Economy Government
Tickers F GM TSLA
Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure
Via MarketBeat
Topics Lawsuit
Tickers ZG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.